According to a Reuters article, Sanofi has filed a lawsuit in New Jersey accusing Novo Nordisk of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its own diabetes drug.
The complaint was filed in U.S. District Court for the District of New Jersey on Dec. 23, and Sanofi wants Novo Nordisk to pay monetary damages and discontinue using those marketing materials for its drug Tresiba.
Read the Reuters story